Open Access Articles- Top Results for Amprenavir


File:Amprenavir skeletal.svg
Systematic (IUPAC) name
(3S)-oxolan-3-yl N-[(2S,3R)-3-hydroxy-4-[N-(2-methylpropyl)(4-aminobenzene)sulfonamido]-1-phenylbutan-2-yl]carbamate
Clinical data
Trade names Agenerase
AHFS/ monograph
MedlinePlus a699051
Licence data EMA:Link, US FDA:link
  • US: C (Risk not ruled out)
Pharmacokinetic data
Protein binding 90%
Metabolism hepatic
Half-life 7.1-10.6 hours
Excretion <3% renal
161814-49-9 7pxY
PubChem CID 65016
DrugBank DB00701 7pxY
ChemSpider 58532 7pxY
UNII 5S0W860XNR 7pxY
KEGG D00894 7pxY
ChEBI CHEBI:40050 7pxY
NIAID ChemDB 006080
Chemical data
Formula C25H35N3O6S
505.628 g/mol
 14pxY (what is this?)  (verify)

Amprenavir (Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in eight very large gel capsules.

Production of amprenavir was discontinued by the manufacturer December 31, 2004; a prodrug version (fosamprenavir) is available.

File:3nu3 478.png
HIV-1 Protease dimer with Amprenavir (sticks) bound in the active site. PDB entry 3nu3 [1]


Research aimed at development of renin inhibitors as potential antihypertensive agents had led to the discovery of compounds that blocked the action of this peptide cleaving enzyme. The amino acid sequence cleaved by renin was found to be fortuitously the same as that required to produce the HIV peptide coat. Structure–activity studies on renin inhibitors proved to be of great value for developing HIV protease inhibitors. Incorporation of an amino alcohol moiety proved crucial to inhibitory activity for many of these agents. This unit is closely related to the one found in the statine, an unusual amino acid that forms part of the pepstatin, a fermentation product that inhibits protease enzymes.



R.D. Tung, M.A. Murcko, G.R. Bhisetti, U.S. Patent 5,558,397 (1996). The scheme shown here is partly based on that used to prepare darunavir and fosamprenavir due to difficulty in deciphering the patent.

See also

External links

  1. ^ Shen, C. H.; Wang, Y. F.; Kovalevsky, A. Y.; Harrison, R. W.; Weber, I. T. (2010). "Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters". FEBS Journal 277 (18): 3699–3714. PMC 2975871. PMID 20695887. doi:10.1111/j.1742-4658.2010.07771.x.  edit
  2. ^ doi:10.1021/jm00054a014
    This citation will be automatically completed in the next few minutes. You can jump the queue or expand by hand

Lua error in package.lua at line 80: module 'Module:Buffer' not found.